Zooming in additional, there’s one explicit sort of insulating materials positioned between the chip and the construction beneath it; this materials, referred to as dielectric movie, is produced in sheets as skinny as white blood cells.
For 30 years, a single Japanese firm referred to as Ajinomoto has made billions producing this explicit movie. Competitors have struggled to outdo them, and right this moment Ajinomoto’s merchandise are utilized in every thing from laptops to information facilities.
Now, a startup primarily based in Berkeley, California, is embarking on a herculean effort to dethrone Ajinomoto and produce this small slice of the chipmaking provide chain again to the US. But success is way from assured. Read the total story.
—James O’Donnell
The effort to make a breakthrough most cancers remedy cheaper
CAR-T therapies, created by engineering a affected person’s personal cells to combat most cancers, are usually reserved for individuals who have exhausted different therapy choices. But final week, the FDA permitted Carvykti, a CAR-T product for a number of myeloma, as a second-line remedy. That means individuals are eligible to obtain Carvykti after their first relapse.
While this implies some a number of myeloma sufferers within the US will now get earlier entry to CAR-T, the overwhelming majority of sufferers across the globe nonetheless received’t get CAR-T in any respect. These therapies are costly—half one million {dollars} in some circumstances. But have they got to be? Read the total story.